Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Acquisition

6 Jul 2007 07:01

Cello Group plc06 July 2007 6 July 2007 Cello Group plc Cello expands financial services capability with the acquisition of cchm:ping Cello Group plc ("Cello", AIM: CLL), the market research and consulting group,has acquired a controlling interest in Hill Murray Group Limited, the holdingcompany of cchm:ping Limited ("cchm:ping"), a specialist financial servicesmarketing agency with options to acquire the balance of the shares. The totalmaximum consideration for the acquisition of 100% of Hill Murray Group Limitedis approximately £5.3 million in cash, loan notes and new ordinary shares. cchm:ping, which was established in 1997, has a number of blue chip financialservices clients including Aegon, Bristol & West Mortgages, Legal & General,Nationwide, Lloyds TSB & Scottish Life. Cello has acquired just over 76% of cchm:ping for an initial consideration ofapproximately £0.95 million of which £0.76 million is payable in cash and thebalance satisfied by the issue of 127,307 new ordinary shares. The remaining 24%is subject to put and call options exercisable in the period 2008 to 2011 withthe option prices being determined by the financial performance of cchm:pingduring the period to 31 December 2010. The option consideration is payable incash, loan notes and new ordinary shares with a minimum amount to be settled incash, loan notes varying from 80% for an option exercised in 2008 to 25% for anoption exercised in 2011. As part of the transaction Cello has also agreed to acquire a controllinginterest (60% on a fully diluted basis) in the issued share capital of thefinancial services consultancy, The Consultancy Practice Limited. The remainingminority interest is the subject of a put option whereby Cello can be requiredto purchase the 40% minority interest at any time in the period from March 2010to March 2013. The option consideration is payable in a mixture of cash, loannotes and new ordinary shares at Cello's discretion with a minimum loan noteconsideration of 25% for an option exercised before March 2011 and 35%thereafter. The maximum option consideration price is £1.75million and is basedon demanding performance related criteria. For the year to 30 September 2006, cchm:ping had an audited turnover of £8.0million, gross profits of £5.6million and delivered a loss before tax of £0.3million. Net assets as at 30 September 2006 were £0.7 million including cash of£0.6 million. Application has been made to the London Stock Exchange for the new shares to beadmitted to AIM and it is expected that admission will take place by 12 July2007. Kevin Steeds, Cello Chairman, said: "cchm:ping is a highly regarded specialist financial services marketing agencywith an excellent client base. As part of our Response division, based inLondon, it will complement our existing business and give us considerably moredepth in the financial services sector vertical." Enquiries: Cello GroupKevin Steeds, Executive Chairman 020 7812 8460 College HillAdrian Duffield/Ben Way 020 7457 2020 Notes to Editors (www.cellogroup.co.uk) Cello is a market research and consulting group that listed on AIM in November2004. The Group's strategy is to create value for shareholders by building a portfolioof research and consulting businesses capable of advising blue chip clientsglobally. Cello has annualised turnover in excess of £90million, gross profits of over £50million and employs approx 550 professional staff. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Jun 20181:24 pmRNSBlock listing Interim Review
29th May 20183:45 pmRNSDirector/PDMR Dealings and Total Voting Rights
9th May 20181:14 pmRNSResult of AGM
9th May 20187:00 amRNSAGM Statement
30th Apr 20182:58 pmRNSTotal Voting Rights
26th Apr 20189:45 amRNSChange of Name
25th Apr 20184:45 pmRNSChange of Name update
23rd Apr 201810:28 amRNSChange of name to Cello Health Group plc
16th Apr 20189:30 amRNSAnnual Report and Notice of AGM
22nd Mar 20187:00 amRNSFinal Results
27th Feb 20183:38 pmRNSTotal Voting Rights
18th Jan 20187:00 amRNSPre Close Trading Statement
23rd Nov 20173:54 pmRNSHolding(s) in Company
31st Oct 201711:16 amRNSTotal Voting Rights
26th Oct 20172:37 pmRNSDirector/PDMR Shareholding
29th Sep 20173:43 pmRNSGrant of Options
27th Sep 20174:59 pmRNSDirector/PDMR Shareholding
22nd Sep 201712:05 pmRNSDirector/PDMR Shareholding
20th Sep 20173:58 pmRNSHolding(s) in Company
20th Sep 201711:52 amRNSAdditional Block Listing of Ordinary Shares
20th Sep 20177:00 amRNSInterim Results
31st Aug 20173:19 pmRNSTotal Voting Rights
31st Jul 20173:06 pmRNSTotal Voting Rights
19th Jul 20177:00 amRNSPre Close Trading Statement
18th Jul 20177:00 amRNSAcquisition of Advantage Healthcare Inc
30th Jun 201712:31 pmRNSTotal Voting Rights
23rd Jun 201712:23 pmRNSHolding(s) in Company
14th Jun 201711:33 amRNSDirector/PDMR Shareholding
31st May 201710:27 amRNSTotal Voting Rights
18th May 20172:13 pmRNSHolding(s) in Company
10th May 20175:18 pmRNSHolding(s) in Company
9th May 20172:55 pmRNSResult of AGM
9th May 20177:00 amRNSAGM Statement
2nd May 20173:15 pmRNSIssue of Equity
13th Apr 20172:40 pmRNSAnnual Report and notice of Annual General Meeting
4th Apr 20175:44 pmRNSBlock listing Interim Review
31st Mar 201710:43 amRNSTotal Voting Rights
28th Mar 20173:03 pmRNSHolding(s) in Company
22nd Mar 20177:00 amRNSPreliminary Results
21st Feb 20171:30 pmRNSHolding(s) in Company
20th Feb 20173:19 pmRNSHolding(s) in Company
20th Feb 20179:29 amRNSTotal Voting Rights
17th Feb 201710:40 amRNSResult of General Meeting
1st Feb 20177:00 amRNSPlacing & Acquisition of Defined Health
19th Jan 20177:00 amRNSPre close trading statement
31st Oct 20163:58 pmRNSTotal Voting Rights
28th Oct 201611:37 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSDirectorate Change
5th Oct 20164:32 pmRNSDirector/PDMR Shareholding
23rd Sep 20165:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.